Check out some anticipated series in the video above or the slideshow gallery below, followed by the full list of new Fall season 2024 anime and where to watch them in the U.S. and their ...

esmo group has launched its latest product—the Apollo Quad Handler. Designed to bridge the gap between the engineering and ...

Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from the sovleplenib ESLIM-01 Phase III trial, as well as several investigator-initiated studies of compounds ...

Portland voters wanted new options. Now we have them—so, so many of them. When ballots arrive in mailboxes this week, Portlanders will be confronted with a list of candidates the length of a ...

Merus’ zenocutuzumab is nearing FDA approval, and petosemtamab shows promise. Learn why MRUS stock could rise as the company ...

We recently saw those results that were published in [European Society for Medical Oncology (ESMO) Open]. 0:54 | Essentially, ...

Phase 3 registrational trials evaluating petosemtamab in combination with pembrolizumab in 1L and petosemtamab monotherapy in 2/3L r/m HNSCC ...

Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary b ...

Q3 2024 Earnings Call Transcript October 30, 2024 Summit Therapeutics Inc. misses on earnings expectations. Reported EPS is $-0.08 EPS, expectations were $-0.07. Operator: Good morning. And welcome to ...

Q3 2024 Earnings Call Transcript October 29, 2024 Incyte Corporation misses on earnings expectations. Reported EPS is $1.07 ...

An expert discussed how patients with breast cancer, particularly those with a BRCA mutation, should consider future ...

In an interview with Targeted Oncology, Peter Schmid, MD, PhD, discussed the results from the phase 3 KEYNOTE-522 trial.